Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Assistenzarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
WiSe 2025
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation lossIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), 2025, in pressDOI (Open Access)
-
Neonatal melanoma with lymph node metastasisIn: EJC Skin Cancer, Jg. 3, 2025, 100281DOI (Open Access)
-
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusIn: Frontiers in Immunology, Jg. 16, 2025, 1536642DOI, Online Volltext (Open Access)
-
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyIn: European Journal of Cancer (EJC), Jg. 220, 2025, 115337DOI (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology, Jg. 15, 2024, 1383125DOI (Open Access)
-
Deep learning based histological classification of adnex tumorsIn: European Journal of Cancer (EJC), Jg. 196, 2024, 113431
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC), Jg. 210, 2024, 114295DOI (Open Access)
-
S1-Guideline Sebaceous CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 22, 2024, Nr. 5, S. 730 – 747DOI (Open Access)
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC), Jg. 208, 2024, 114208DOI (Open Access)
-
Applying an artificial intelligence deep learning approach to routine dermatopathological diagnosis of basal cell carcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 21, 2023, Nr. 11, S. 1329 – 1337
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC), Jg. 183, 2023, S. 1 – 10
-
Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndromeIn: European Journal of Human Genetics, Jg. 31, 2023, Nr. 11, S. 1261 – 1269DOI (Open Access)
-
Clinical, histopathological and molecular features of dedifferentiated melanomas : An EORTC Melanoma Group Retrospective AnalysisIn: European Journal of Cancer (EJC), Jg. 187, 2023, S. 7 – 14DOI (Open Access)
-
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma ADOREG/TRIM : Analysis of the DeCOG prospective multicenter cohort studyIn: eBioMedicine, Jg. 96, 2023, 104774DOI (Open Access)
-
Deep learning detection of melanoma metastases in lymph nodesIn: European Journal of Cancer (EJC), Jg. 188, 2023, S. 161 – 170
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research, Jg. 29, 2023, Nr. 15, S. 2894 – 2907
-
Human Papillomavirus 42 Drives Digital Papillary Adenocarcinoma and Elicits a Germ Cell-like Program Conserved in HPV-Positive CancersIn: Cancer Discovery, Jg. 13, 2023, Nr. 1, S. 70 – 84DOI (Open Access)
-
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma : a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC), Jg. 188, 2023, S. 140 – 151DOI, Online Volltext (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology, Jg. 36, 2022, Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 – 44DOI (Open Access)
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine, Jg. 12, 2022, Nr. 11, e1090DOI, Online Volltext (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research, Jg. 35, 2022, Nr. 6, S. 573 – 586DOI (Open Access)
-
Deep Learning Assisted Diagnosis of Onychomycosis on Whole-Slide ImagesIn: Journal of Fungi, Jg. 8, 2022, Nr. 9, 912DOI, Online Volltext (Open Access)
-
Evaluation of a Deep Learning Approach to Differentiate Bowen’s Disease and Seborrheic KeratosisIn: Cancers, Jg. 14, 2022, Nr. 14, 3518DOI (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers, Jg. 14, 2022, Nr. 9, 2090DOI, Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers, Jg. 14, 2022, Nr. 17, 4066DOI, Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer, Jg. 151, 2022, Nr. 9, S. 1542 – 1554DOI (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC), Jg. 166, 2022, S. 60 – 72
-
Giant congenital melanocytic naevus caused by NRAS Q61K mosaicismIn: JEADV Clinical Practice, Jg. 1, 2022, Nr. 4, S. 416 – 419DOI, Online Volltext (Open Access)
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology, Jg. 36, 2022, Nr. S1, S. 29 – 34DOI (Open Access)
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC), Jg. 161, 2022, S. 99 – 107DOI, Online Volltext (Open Access)
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS), Jg. 23, 2022, Nr. 6, 3324DOI, Online Volltext (Open Access)
-
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology, Jg. 11, 2021, 725549DOI, Online Volltext (Open Access)
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology, Jg. 11, 2021, 741993DOI, Online Volltext (Open Access)
-
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsIn: Frontiers in Genetics, Jg. 12, 2021, 663272DOI, Online Volltext (Open Access)
-
High-resolution three-dimensional imaging for precise staging in melanomaIn: European Journal of Cancer (EJC), Jg. 159, 2021, S. 182 – 193DOI (Open Access)
-
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 19, 2021, Nr. 8, S. 1217 – 1219DOI (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC), Jg. 148, 2021, S. 340 – 347DOI, Online Volltext (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC), Jg. 159, 2021, S. 113 – 124
-
Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular TumorsIn: Dermato, Jg. 1, 2021, Nr. 1, S. 18 – 25DOI (Open Access)
-
Response to comment : Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC), Jg. 157, 2021, S. 514 – 515
-
Sarcoma classification by DNA methylation profilingIn: Nature Communications, Jg. 12, 2021, Nr. 1, S. 498DOI (Open Access)
-
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 TreatmentIn: Cancer Immunology Research, Jg. 8, 2020, Nr. 9, S. 1163 – 1179DOI, Online Volltext (Open Access)
-
Deep Penetrating Nevus and Borderline-Deep Penetrating Nevus : A Literature ReviewIn: Frontiers in Oncology, Jg. 10, 2020, S. 837DOI (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 18, 2020, Nr. 10, S. 1165 – 1168DOI (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD, Jg. 183, 2020, Nr. 5, S. 928 – 939DOI (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist, Jg. 61, 2020, Nr. 7, S. 669 – 675DOI (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe, Jg. 26, 2020, Nr. 8, S. 713 – 720
-
Re: Deep learning outperformed 11 pathologists in the classification of histopathological melanoma imagesIn: European Journal of Cancer (EJC), Jg. 130, 2020, S. 259 – 261DOI (Open Access)
-
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyIn: The Journal of Clinical Investigation (JCI), Jg. 130, 2020, Nr. 8, S. 4266 – 4281DOI, Online Volltext (Open Access)
-
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer (EJC), Jg. 111, 2019, S. 148 – 154DOI (Open Access)
-
An Animal Model of Cutaneous Cyst Development Enables the Identification of Three Quantitative Trait Loci, Including the Homologue of a Human Locus (TRICY1)In: Journal of Investigative Dermatology, Jg. 139, 2019, Nr. 10, S. 2235 – 2238.e5DOI (Open Access)
-
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanomaIn: JCO Precision Oncology, Jg. 3, 2019DOI, Online Volltext (Open Access)
-
Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in MelanomaIn: JAMA Network Open, Jg. 2, 2019, Nr. 8, S. e199020DOI (Open Access)
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC), Jg. 119, 2019, S. 66 – 76DOI (Open Access)
-
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer (EJC), Jg. 113, 2019, S. 47 – 54DOI (Open Access)
-
Digitales papilläres Adenokarzinom : Vier Fallberichte mit kurzer LiteraturübersichtIn: Der Hautarzt, Jg. 70, 2019, Nr. 3, S. 204 – 209
-
Frequent Occurrence of NRAS and BRAF Mutations in Human Acral NaeviIn: Cancers, Jg. 11, 2019, Nr. 4, S. 546DOI, Online Volltext (Open Access)
-
Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotypeIn: Clinical Sarcoma Research, Jg. 9, 2019, 2DOI (Open Access)
-
Prognostic significance of NAB2–STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS : not (yet) clearIn: Acta Neuropathologica, Jg. 137, 2019, Nr. 4, S. 679 – 682DOI, Online Volltext (Open Access)
-
Proton radiotherapy in advanced malignant melanoma of the conjunctivaIn: Graefes Archive for Clinical and Experimental Ophthalmology, Jg. 257, 2019, Nr. 6, S. 1309 – 1318
-
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in MelanomaIn: Cell Reports, Jg. 27, 2019, Nr. 12, S. 3573 – 3586.e7DOI (Open Access)
-
ctDNA as a noninvasive monitoring tool in metastatic melanomaIn: Journal of Clinical Oncology (JCO), Jg. 37, 2019, Nr. Suppl. 15, S. 9548
-
Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profilesIn: Modern Pathology, Jg. 31, 2018, Nr. 3, S. 418 – 428DOI, Online Volltext (Open Access)
-
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaIn: Cell Reports, Jg. 22, 2018, Nr. 9, S. 2455 – 2468DOI (Open Access)
-
Integrated genomic classification of melanocytic tumors of the central nervous system using mutation analysis, copy number alterations, and DNA methylation profilingIn: Clinical Cancer Research, Jg. 24, 2018, Nr. 18, S. 4494 – 4504DOI (Open Access)
-
Intraventricular melanocytoma diagnosis confirmed by gene mutation profileIn: Neuropathology, Jg. 38, 2018, Nr. 3, S. 288 – 292
-
Konjunktivales Melanom : Standardisiertes Vorgehen in Diagnostik, Therapie und NachsorgeIn: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, Jg. 115, 2018, Nr. 6, S. 489 – 498
-
NF1 mutations in conjunctival melanomaIn: British Journal of Cancer (BJC), Jg. 118, 2018, Nr. 9, S. 1243 – 1247DOI (Open Access)
-
Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term TherapyIn: Molecular Imaging and Biology, Jg. 20, 2018, Nr. 1, S. 124 – 130
-
Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912)In: Ophthalmology, Jg. 125, 2018, Nr. 11, S. e78 – e79
-
The genetic basis for most patients with pustular skin disease remains elusiveIn: British Journal of Dermatology: BJD, Jg. 178, 2018, Nr. 3, S. 740 – 748DOI (Open Access)
-
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy ResistanceIn: Journal of the National Cancer Institute (JNCI), Jg. 110, 2018, Nr. 6, S. 677 – 681DOI (Open Access)
-
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications, Jg. 8, 2017, 15440DOI (Open Access)
-
Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic TumorsIn: Journal of Investigative Dermatology, Jg. 137, 2017, Nr. 9, S. 2033 – 2035
-
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue neviIn: Modern Pathology, Jg. 30, 2017, Nr. 3, S. 350 – 356DOI, Online Volltext (Open Access)
-
Epidermal growth factor receptor gaining impact in cutaneous squamous cell carcinomaIn: British Journal of Dermatology: BJD, Jg. 176, 2017, Nr. 5, S. 1126 – 1127
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science (IOVS), Jg. 58, 2017, Nr. 9, S. 3464 – 3470DOI (Open Access)
-
Integrative analysis identifies four molecular and clinical subsets in uveal melanomaIn: Cancer Cell, Jg. 32, 2017, Nr. 2, S. 204 – 220.e15DOI (Open Access)
-
Melanoma diagnosed in lesions previously treated by laser therapyIn: The Journal of Dermatology, Jg. 44, 2017, Nr. 1, S. 23 – 28
-
Next-Generation Sequencing to Guide Treatment of Advanced MelanomaIn: American Journal of Clinical Dermatology, Jg. 18, 2017, Nr. 3, S. 303 – 310
-
Role of mutational status of GNAQ and GNA11 in the diagnosis of melanocytic tumors : ResponseIn: Journal of Neurosurgery (JNS), Jg. 126, 2017, Nr. 3, S. 1024 – 1026
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology, Jg. 30, 2017, Nr. 7, S. 928 – 939DOI, Online Volltext (Open Access)
-
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget, Jg. 8, 2017, Nr. 25, S. 40683 – 40692DOI (Open Access)
-
Biomarkers in melanomaIn: Scandinavian Journal of Clinical and Laboratory Investigation, Jg. 76, 2016, Nr. Suppl. 245, S. S104 – S112
-
Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation SignatureIn: Journal of Investigative Dermatology, Jg. 136, 2016, Nr. 7, S. 1526 – 1528
-
High TERT promoter mutation frequency in non-acral cutaneous metastatic melanomaIn: Pigment Cell and Melanoma Research, Jg. 29, 2016, Nr. 5, S. 598 – 600
-
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencyIn: Cancer Research, Jg. 76, 2016, Nr. 15, S. 4347 – 4358
-
Molekulare und immunhistochemische Diagnostik beim MelanomIn: Der Hautarzt, Jg. 67, 2016, Nr. 7, S. 511 – 518
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer (EJC), Jg. 57, 2016, S. 112 – 117
-
Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNAIn: OncoTarget, Jg. 7, 2016, Nr. 37, S. 59115 – 59128DOI (Open Access)
-
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemIn: Journal of Neuro-Oncology, Jg. 127, 2016, Nr. 3, S. 435 – 444DOI, Online Volltext (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 13, 2015, Nr. Suppl. 2, S. 11
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget, Jg. 6, 2015, Nr. 28, S. 25868 – 25882DOI (Open Access)
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE, Jg. 10, 2015, Nr. 4, S. e0124590DOI (Open Access)
-
Die multispektraloptoakustische Tomographie (MSOT) zur nichtinvasiven Diagnostik des Schildwächterlymphknotens bei Patienten mit malignem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 13, 2015, Nr. 12, S. 1323
-
Frequent TERT Promoter Mutations in Ocular Surface Squamous NeoplasiaIn: Investigative Ophthalmology & Visual Science (IOVS), Jg. 56, 2015, Nr. 10, S. 5854 – 5861DOI (Open Access)
-
Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningiomaIn: Neuropathology, Jg. 35, 2015, Nr. 1, S. 24 – 36
-
Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imagingIn: Immunotherapy, Jg. 7, 2015, Nr. 317, S. 317ra199
-
Molekulare Diagnostik bei melanozytären TumorenIn: Der Pathologe, Jg. 36, 2015, Nr. 1, S. 30 – 36
-
Panel Sequencing MelanomasIn: Journal of Investigative Dermatology, Jg. 135, 2015, Nr. 2, S. 335 – 336DOI (Open Access)
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE, Jg. 10, 2015, Nr. 3, S. e0118564DOI (Open Access)
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology, Jg. 26, 2015, Nr. 1, S. 250 – 251
-
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayIn: OncoTarget, Jg. 6, 2015, Nr. 34, S. 36041 – 36052DOI (Open Access)
-
Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous systemIn: Neuropathology and Applied Neurobiology, Jg. 40, 2014, Nr. 6, S. 794 – 797
-
Angioplasmacellular hyperplasia - a new histopathologic clue for anogenital herpes simplex recidivans in immunocompromised patients?In: American Journal of Dermatopathology, Jg. 36, 2014, Nr. 10, S. 822 – 826
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology, Jg. 25, 2014, Nr. 3, S. 747 – 753
-
Genetic alterations and personalized medicine in melanoma: Progress and future prospectsIn: Journal of the National Cancer Institute (JNCI), Jg. 106, 2014, Nr. 2, S. djt435
-
Genetic and clinico-pathologic analysis of metastatic uveal melanomaIn: Modern Pathology, Jg. 27, 2014, Nr. 2, S. 175 – 183
-
Genetic evolution of T-cell resistance in the course of melanoma progressionIn: Clinical Cancer Research, Jg. 20, 2014, Nr. 24, S. 6593 – 6604
-
Immune Modulating Effects of NKT Cells in a Physiologically Low Dose Leishmania major Infection Model after αGalCer Analog PBS57 StimulationIn: PLoS Neglected Tropical Diseases, Jg. 8, 2014, Nr. 6, S. e2917DOI (Open Access)
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute (JNCI), Jg. 106, 2014, Nr. 9
-
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasIn: Modern Pathology, Jg. 27, 2014, Nr. 4, S. 502 – 508DOI (Open Access)
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 30, S. 3844 – 3845
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research, Jg. 19, 2013, Nr. 22, S. 6331 – 6332
-
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomasIn: Clinical Cancer Research, Jg. 19, 2013, Nr. 12, S. 3143 – 3152
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 11, 2013, Nr. 9, S. 952 – 952
-
Lack of SF3B1 R625 mutations in cutaneous melanomaIn: Diagnostic Pathology, Jg. 8, 2013, S. 87DOI (Open Access)
-
New developments in biomarkers for melanomaIn: Current Opinion in Oncology, Jg. 25, 2013, Nr. 2, S. 145 – 151
-
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinomaIn: PLoS ONE, Jg. 8, 2013, Nr. 11, S. e80354DOI (Open Access)
-
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumoursIn: British Journal of Cancer (BJC), Jg. 109, 2013, Nr. 2, S. 497 – 501DOI (Open Access)
-
Tumor regression and sirolimus-based therapy in lung transplantationIn: The Journal of Heart and Lung Transplantation, Jg. 32, 2013, Nr. 9, S. 938 – 939
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: Cancer Research, Jg. 73, 2013, Nr. 8 Suppl., S. 4714
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: International Journal of Cancer, Jg. 133, 2013, Nr. 7, S. 1653 – 1663
-
Genetic and molecular characterization of uveal melanoma cell linesIn: Pigment Cell and Melanoma Research, Jg. 25, 2012, Nr. 2, S. 182 – 187
-
PD-L1 Expression in Lymph Node Metastases as a Predictor of adjuvant Immunotherapy Success in Stage III Melanoma Patients: An Analysis of the prospective ADOREG Study TRIM-ADJUVANTIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 22, 2024, Nr. Suppl. 4, S. 15 – 16
-
Außergewöhnlicher Therapiebenefit von Imatinib bei cKIT-mutiertem Schleimhautmelanom mit nachfolgendem KIT-Mutationsverlust
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21 – 22DOI (Open Access) -
Die PD-L1-Expression im Tumor prognostiziert je nach Art des untersuchten Gewebes das Outcome einer Anti-PD-1-basierten Immuntherapie bei metastasiertem Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 27 – 28DOI (Open Access) -
Etablierung eines Mustererkennungsalgorithmus zur histologischen Detektion von Melanommetastasen im Schildwächterlymphknoten
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 20 – 21DOI (Open Access) -
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21DOI (Open Access) -
Untersuchung des klinischen Verlaufs von Melanompatienten mit einer Super-Response (CR/PR innerhalb von 3 Monaten) unter PD-1-basierter Immuncheckpoint-Inhibition : eine Subgruppen-Analyse der prospektiven multizentrischen Studie ADOREG
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 8 – 9DOI (Open Access) -
Etablierung eines Deep-Learning-Algorithmus zur Differenzierung von Morbus Bowen und seborrhoischen Keratosen
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 15 -
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 12 – 13 -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 6 -
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 59 – 60
-
Interferon-independent enhancement of melanoma cell immunogenicity by RIG-I activation
47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) Virtual, March 04‐06, 2021,In: Experimental Dermatology. Hoboken: Wiley, Jg. 30, 2021, Nr. 3, S. E78 -
PD-L1-Expression and Mutation Profile in pre-therapeutic Tumor Tissue as Predictors of the Therapeutic Success of PD-1-based Immune Checkpoint Inhibition Therapy in Patients with metastatic Melanoma : Evaluation of the prospective multicentric ADO-Study TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 19
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 6 – 7
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 31
-
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma : A prospective multicenter DeCOG studyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 9568 – 9568DOI (Open Access)
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 58 – 59
-
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 18, 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36DOI (Open Access)
-
Eindrucksvolles und schnelles Therapieansprechen eines metastasierten Adnexkarzinoms unter CemiplimabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 18, 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV08DOI (Open Access)
-
RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodiesIn: Journal for ImmunoTherapy of Cancer. London: BMJ, Jg. 8, 2020, Nr. Suppl. 2, S. A3DOI (Open Access)
-
Tumorzell‐intrinsiche Aktivierung des Immunrezeptors RIG‐I in Kombination mit Immun‐Checkpoint‐Blockade verbessert anti‐Tumor T‐ZellantwortenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 18, 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV18DOI (Open Access)
-
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. Suppl. 6, S. 3
-
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 7 – 8DOI (Open Access)
-
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 3DOI (Open Access) -
Oncogene and copy number analysis of a larger cohort of conjunctival melanomaIn: Experimental Dermatology. Hoboken: Wiley, Jg. 22, 2013, Nr. 3, S. E43
-
Die Aufdeckung genetischer Alterationen bei kutanen und okularen NeoplasienDuisburg, Essen, 2014
-
High-resolution 3-D imaging for precise staging in malignant melanomaNew York, 2020DOI, Online Volltext (Open Access)
-
Ausgedehntes Rezidiv eines atypischen Fibroxanthoms
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 99DOI (Open Access) -
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 – 77DOI (Open Access) -
Role of IFNγ-induced tumor-T cell equilibrium in melanoma latencyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 34DOI (Open Access)
-
Therapieansprechen auf Sunitinib bei Imatinib-resistentem Rezidiv eines Dermatofibrosarkoma protuberans am Capillitium
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 99 – 100DOI (Open Access) -
Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S695 -
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 84 -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 88 -
3D data related to : Identification and quantification of hidden melanoma metastases in human sentinel lymph nodes using light sheet fluorescence microscopy2020DOI, Online Volltext (Open Access)